Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)
Public ClinicalTrials.gov record NCT00116298. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Study to Compare Long-Term Safety and Tolerability of Stavudine (d4T) Extended Release (ER) Versus Conventional (Immediate Release, IR) Formulations, Each In Combination With Lamivudine (3TC) and Efavirenz (EFV) in Subjects Who Have Completed BMS Studies AI455-096 and AI455-099
Study identification
- NCT ID
- NCT00116298
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 900 participants
Conditions and interventions
Conditions
Interventions
- stavudine, efavirenz, lamivudine Drug
Drug
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2000
- Primary completion
- Dec 31, 2004
- Completion
- Dec 31, 2004
- Last update posted
- Apr 24, 2011
2001 – 2005
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution | Berkeley | California | — | — |
| Local Institution | Los Angeles | California | — | — |
| Local Institution | West Hollywood | California | — | — |
| Local Institution | Washington D.C. | District of Columbia | — | — |
| Local Institution | Fort Lauderdale | Florida | — | — |
| Local Institution | Orlando | Florida | — | — |
| Local Institution | Tampa | Florida | — | — |
| Local Institution | Indianapolis | Indiana | — | — |
| Local Institution | Wichita | Kansas | — | — |
| Local Institution | Louisville | Kentucky | — | — |
| Local Institution | Brookline | Massachusetts | — | — |
| Local Institution | Las Vegas | Nevada | — | — |
| Local Institution | Reno | Nevada | — | — |
| Local Institution | New York | New York | — | — |
| Local Institution | Winston-Salem | North Carolina | — | — |
| Local Institution | Oklahoma City | Oklahoma | — | — |
| Local Institution | Dallas | Texas | — | — |
| Local Institution | Houston | Texas | — | — |
| Local Institution | Hampton | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00116298, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 24, 2011 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00116298 live on ClinicalTrials.gov.